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A docking and modelling strategy for peptide–RNA complexes:
applications to BIV Tat–TAR and HIV Rev–RBE
Jayashree Srinivasan1,2, Fabrice Leclerc1, Wei Xu3, Andrew D Ellington3
and Robert Cedergren1
Background: In spite of the great interest in the interaction between RNAs and
proteins, no general protocol for modelling these complexes is presently
available. This methodological vacuum is particularly acute because the structure
of few such complexes is known.
Results: A general strategy for docking and modelling RNA–protein complexes
has been developed. The docking procedure involves minimizing electrostatic
and van der Waals’ interaction energies of conformationally rigid structures
during docking. After docking, libraries of amino acid sidechain conformations
are searched to obtain the best interactions between the peptide and the RNA.
Using this method, we have reproduced the structure of a bovine
immunodeficiency virus (BIV) Tat peptide bound to BIV TAR RNA and have
developed a model for the structure of the arginine-rich HIV-1 Rev peptide
(Rev34–50) interacting with the Rev-binding element (RBE). 
Conclusions: The resulting model of the Rev34–50–RBE complex predicts that
although no single arginine sidechain is responsible for complex formation,
residues Arg2, Arg5 and Arg11 are more important for binding than the other
arginine residues in the peptide. One model is supported by binding
measurements performed on wild-type and mutant RBE molecules with 
the peptide.
Introduction
The three-dimensional modelling of a macromolecule,
such as RNA, is not yet a straightforward exercise, and the
modelling of complexes involving proteins and RNA is
subject to a number of additional complications. The
docking problem for proteins has been widely recognized
and innovative methods have been developed to generate
realistic models of interactions between polypeptides and
ligands [1,2]. Interactions between nucleic acids and pro-
teins, however, have so far proven more difficult to model.
In fact, attempts to model nucleic acid complexes have
previously been largely restricted to DNA–drug com-
plexes [3,4]. The number of nucleic acid–protein com-
plexes whose structures have been solved to atomic
resolution has been limited and, until recently, there were
few examples to guide model-building exercises. In addi-
tion, less is known about the mutual adjustments that are
required to maximize interactions between inherently
deformable RNA and protein molecules.
Recent work on the structure of peptide–RNA complexes
has provided critical information for directing model build-
ing (reviewed in [5]). Peptides derived from the bovine
immunodeficiency virus (BIV) Tat protein can bind
specifically to the BIV TAR element. The structures of
two BIV Tat peptide–TAR complexes have been solved
by multidimensional NMR analysis [6,7] and provide a
convenient control to assess methods for docking and
modelling. Similarly, a 17 amino acid peptide derived from
residues 34–50 of the human immunodeficiency virus Rev
protein (Rev34–50; Fig. 1a) can specifically bind to a 30
nucleotide RNA, the Rev-binding element (RBE [8–10];
Fig. 1b). We have previously modelled the structure of the
RBE [11], and NMR analyses confirmed key aspects of
our prediction [12,13]. A unique pattern of canonical and
noncanonical base pairs [14–16] is thought to substantially
widen the major groove of the RBE and permit access of
amino acids in the Rev peptide to normally unapproach-
able nucleotide functional groups in the RNA [5,11].
However, at the time that our study was performed, the
precise structure of the Rev–RBE complex was not
known, and this system therefore provided a means to
assess whether our methods could accurately predict inter-
actions between peptides and nucleic acids. We present in
detail a strategy for the docking and modelling of the
complex between the Rev peptide and the RBE.
Results
The modelling process
Computational methods used to construct molecular com-
plexes involve the search for optimal intermolecular geom-
etry and interaction energy. A rigorous search in geometric
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space involves a large number of trajectories, each of
which is a rugged energy surface where small changes in
intermolecular distance and orientation can result in large
changes in interaction energy. To streamline this process,
fully automated strategies to model protein–protein com-
plexes have been developed based on either a geometric
method, i.e. a search for complementarity between the
ligand and substrate binding surfaces, or an energy-driven
method, i.e. minimization of their interaction energy [1,2].
Unfortunately, these methods have yet to address nucleic
acid–protein interactions. Thus, we have established an
obvious but robust hierarchy for energetic analysis and
have used this hierarchy to develop a generally useful
docking algorithm. First, the structures of the individual
molecules are energetically minimized independently and
then treated as rigid bodies during the docking procedure.
Next, the molecules are brought into contact along a small
set of trajectories dictated by experimental data. Since
nucleic acids are predominantly negatively charged while
the proteins interacting with them are frequently posi-
tively charged, their interaction energies are largely elec-
trostatic. Thus, the trajectory that gives the best initial
minimization of electrostatic and van der Waals’ interac-
tions is retained. Finally, the juxtapositions of the partners
and the positions of sidechains along the most favourable
trajectory are extensively analyzed. The steps involved in
modelling a test complex between BIV Tat peptide and
TAR RNA and a peptide from the HIV-1 Rev protein,
Rev34–50, and the RBE are shown in Figure 2.
The BIV Tat–TAR complex
In order to validate the docking algorithm, we first applied
it to a known structure, the BIV Tat–TAR complex [6].
Specifically, we have tested the ability of the method to
identify the correct orientation (5′,3′ relative to N and C
termini) and register (juxtaposition) of the Tat peptide
within the RNA recognition site and evaluated its sensi-
tivity to small changes in peptide register within the
recognition site. In generating these models for the
complex, conformations of both partners were fixed. Start-
ing from the published NMR structure of the complex
(designated R), three other models were constructed. The
inverted model I was obtained by the rotation of the origi-
nal peptide axis 180° about its midpoint while the position
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Figure 1
The sequences of the peptide and RNA involved in the Rev–RBE
complex. (a) Sequence of the Rev34–50 peptide (in the one-letter amino
acid code). The C-terminal modification to form a neutral amide group
was based on the fact that this group increased the helicity of the
sequence compared to the unmodified sequence (AD Ellington,
unpublished data). (b) Primary sequence and secondary structure of
the Rev-binding element (RBE) used in modelling the three-
dimensional structure by the constraint satisfaction algorithm MC-SYM
[11,35,36]. The solid lines indicate Watson–Crick base pairs, dashed
lines indicate noncanonical base pairs and the dotted lines indicate
alternative base pairing schemes. The nucleotide numbering
convention adopted here is the same as in Leclerc et al. [11].
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Figure 2
Flowchart for the docking procedure employed for modelling
peptide–RNA complexes. The programs used at each step are
indicated in italics, and steps involving manual docking are designated
by an asterisk.
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of the RNA was frozen. A second model, R-C2, represent-
ing the case of a complex with the proper orientation but
an incorrect register was constructed by translating the
peptide from its original position one base pair step along
the recognition site towards the 5′,3′ end of the TAR
RNA. A third model, R-C1, was obtained by a 0.5 Å trans-
lation from its original position in the direction of the loop
of the RNA. Calculation of the free energy of binding for
different models confirmed that the free energy of the
complex structure determined by NMR was indeed the
lowest (Table 1). Judging from the free energy of binding
calculated for the model R-C1, the method would be
rather insensitive to small perturbations in peptide regis-
ter. However, these calculations do demonstrate the valid-
ity of using the free energy of binding as a metric for
determining the global register and orientation of peptides
docked with RNA.
Docking the Rev peptide and the RBE 
Having validated our method, we wished to test it on a
previously unknown structure, a complex between the
HIV-1 Rev peptide (Rev34–50) and its cognate RNA, the
RBE. One of the benefits of our procedure is that the
precise geometry of each of the molecules within the
complex need not be known in advance. Since the original
models for the isolated molecules were generated under
the conditions of a complex formed in vivo, the degree to
which they can be brought together to form a tight
complex is an independent measure of their accuracy. The
Rev34–50 peptide was initially modelled as a canonical -
helix, consistent with results from recent binding and cir-
cular dichroism studies [17–19]. Starting structures for the
RBE RNA were taken from our previous modelling study
[11] and differed only in the orientation of residue 71 —
structure ‘A’ had G71 in the anti conformation, whereas
structure ‘S’ had G71 in the syn conformation. They dif-
fered from each other by an all-atom root mean square
deviation (RMSD) of 2.6 Å, but were indistinguishable on
the basis of their electrostatic potential surfaces.
Docking was guided by the electrostatic potential surfaces
(Fig. 3a,b) and published experimental data
[10,14–18,20–22]. Amino acid substitution experiments had
identified arginine residues in the Rev34–50 peptide that
were critical for interaction with the RBE [10,17,21]. These
arginines, Arg2, Arg5, Arg6, Arg9 and Arg13, all lay along
one side of an -helical wheel (Fig. 3c). In vitro selection
experiments [14,16] and modification interference analysis
[10,15,22] had both shown that the major groove of the
RBE internal loop was the site of peptide binding (Fig. 3b).
Initial modelling therefore focused on fitting one face of
the peptide to the major groove of the RNA.
The electrostatic potential surfaces of the RNA and the
peptide were determined. The two molecules were
brought together under the criterion of minimizing both
van der Waals’ and coulombic energies of the nascent
complex. Two different orientations for the peptide were
considered during the docking procedure: one in which
the N-terminal end of the peptide pointed towards the
open end of the RBE (‘NO’) and the other in which it
pointed towards the tetraloop region of RBE (‘NL’). In
conjunction with the two forms of the RNA, ‘A’ and ‘S’,
four different initial models were generated: A–NL,
A–NO, S–NL and S–NO.
Identifying the register of the peptide
The same general techniques that were initially devel-
oped to assess the BIV Tat–TAR structure served to opti-
mize the HIV-1 Rev–RBE models. The peptide was
translated and rotated along its helical axis relative to the
major groove of the RBE. At each local energy minimum,
conformations for the amino acid sidechains on the side
facing the RNA were additionally searched in the case of
the RBE complex in order to promote interactions
between the RNA and the peptide. If the resulting model
was consistent with data from alanine mutation studies of
the peptide [17,21] and chemical protection studies of the
RBE available in the literature [10,15,20], the electrostatic
and van der Waals’ interaction energy of the complex was
then evaluated. Selected models underwent energy mini-
mization (see Materials and methods). The binding ener-
gies for different models of the Rev34–50–RBE complexes
are shown in Table 2.
The lowest energy complex is formed when the N termi-
nus of the Rev34–50 peptide points towards the UUCG
tetraloop region of the RBE (NL orientation) for both the
‘A’ and ‘S’ starting structures of the RBE. For the NL ori-
entation of the peptide, two different registers were con-
sistent with the biochemical data. One juxtaposition is
represented by the model A–NL in which the N-terminal
residues Thr1 and Arg2 of the peptide are aligned with
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Table 1
The free energy of binding determined from the electrostatic
energies of the different BIV Tat–TAR complexes and the
corresponding RNA and peptide molecules.
Model Gbinding
(kcal mol–1)
R –308.5
R-C1 –302.7
R-C2 3.1
I 15.0
The NMR structure of the complex is referred to as R. Model R-C1 has
the peptide shifted about 0.5 Å towards the loop. Model R-C2 has the
same peptide orientation as R but has been shifted by a two base pair
step along the RNA axis towards the 5′,3′ end of the TAR RNA. Model
I (for inverted) features the peptide in the orientation obtained by a
180° rotation about the perpendicular of the helical axis.
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Figure 3
Electrostatic surfaces of the Rev peptide and
RBE RNA. (a) Front and back views of the
electrostatic surface of the Rev34–50 peptide.
Amino acid residues referred to in the text are
shown (in the one-letter amino acid code). 
(b) Electrostatic surface of the RBE viewed
into the major and minor grooves. Phosphate
groups that are protected from chemical
modification due to complex formation are
indicated. (c) Helical wheel projection for the
Rev34–50 peptide. Arginine residues cleaved
strongly (thick arrows) and weakly (thin
arrows) during proteolytic cleavage studies
are shown [20]. Amino acid residues whose
substitution by alanine lead to peptides that
do not form complexes are boxed. 
the base pair step G67–C51. The other juxtaposition is
one in which the entire peptide is shifted two base pairs
towards the tetraloop and thus Thr1 and Arg2 are aligned
with the base pair step G64–C54 (represented as model
A–NL_a). The calculated binding free energy suggested
that the peptide register corresponding to model A–NL
was preferred to that of model A–NL_a (Table 2).
Further, the anti form of the RBE has a lower energy than
the syn form. This finding corroborates both NMR studies
and our earlier conclusion that although the conformation
of the nucleotide G71 is flexible, as suggested both by
NMR and theoretical studies [11–13,23], the anti confor-
mation is preferred in the context of the complex [11].
Interactions between the peptide and the RBE
The best model for the complex, model A–NL, was
further optimized by in vacuo molecular dynamics simula-
tions with intermolecular and intramolecular hydrogen
bonding constraints. The final structure was an average
structure from the 300 K equilibrated trajectory (final 15
ps) of the dynamics simulation (Fig. 4a).
Based on a distance cut-off of 2.5 Å between atoms in
contact, we postulate a series of interactions between the
RBE and the Rev34–50 peptide in model A–NL (Table 3).
Specific interactions between the peptide sidechains and
guanosine base moieties in the RBE provide a ‘direct
read-out’ of the sequence, while nonspecific interactions
between basic and polar peptide sidechains and the phos-
phodiester backbone of the RBE yield an ‘indirect read-
out’ of structure. Hydrogen bonding patterns confirm that
the noncanonical base pairs are preserved in the complex
and are intimately involved in peptide recognition. In
accord with binding studies with substituted peptides
[17,20], most specific contacts to the RNA are made by
arginine and asparagine, while nonspecific contacts are
made by both arginine and other polar amino acid
sidechains. The peptide backbone appears to be involved
in only intramolecular interactions that would be impor-
tant for stabilizing the helical structure.
Role of Arg2, Arg5, Arg11 and Asn7: direct read-out
Model A–NL predicts specific interactions between
residues Arg2, Arg5, and Arg11 of the peptide and the con-
served nucleotides of the RBE internal loop (Table 3).
The sidechain of Arg2 interacts specifically with the O6 of
G67 (base paired to C51). Arg11 interacts with the N7 and
phosphate of G46 (base paired to C74). The guanidino
sidechain of Arg5 takes advantage of its multivalent
hydrogen bonding capacity by making major groove con-
tacts with both the O6 and N7 of G70 (Fig. 4b). It should
be noted that G70 is a critical residue which is invariant in
both the RBE and artificially selected sequences [16].
This pattern of interactions implies that there is no one
critical arginine, but rather that the interactions of residues
Arg2, Arg5 and Arg11 with the invariant residues of the
RNA are vital to complex formation, as suggested previ-
ously from the results of binding studies with alanine sub-
stitutions of the Rev peptide or protein [17,24].
The hydrophilic residue Asn7 contacts the O6 of G47,
which forms a noncanonical base pair with A73. In addi-
tion to this interaction, snapshot structures from the in
vacuo dynamics simulations show that a long-range hydro-
gen bonding interaction between the carbonyl sidechain
of Asn7 and the N6 amino group of A73 are possible. The
G47–A73 noncanonical base pair is again invariant among
the RBE and aptamer sequences [6]. Conversely, this
interaction is absent in the complexes A–NL_a, A–NO
and S–NO, reinforcing the conclusion that the modelled
interaction between the peptide and the RBE is optimal.
Role of Thr1 and Arg6: indirect read-out
The sidechain hydroxyl group of Thr1 is predicted to
hydrogen bond with the 3′-phosphate of G48. This
portion of the model accords with previous suggestions
that the non-Watson–Crick pair between positions 48 and
71 serves to position the phosphate backbone for precise
recognition by the Rev peptide [16]. The threonine may
additionally serve as an end-capping residue to stabilize
the -helical structure of the peptide, since binding affini-
ties of short Rev peptides correlate to their percent helic-
ity in solution [25]. The sidechain of arginine Arg6 also
interacts with a phosphate group, in this case 3′ to the
invariant guanosine residue G70. In addition to these
interactions the three arginine residues, Arg8, Arg9, and
Arg13, form electrostatic contacts with phosphates that lie
along the major groove lining the RBE internal loop
(Table 3). Finally, dynamics simulations indicate that the
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Table 2
The free energy of binding determined from the electrostatic
energies of the complexes and the corresponding RBE and
peptide molecules using the finite difference method to solve
the Poisson–Boltzmann equation.
Model Gbinding
(kcal mol–1)
A-NL –71.6
A–NL_a –21.6
S–NL –46.0
A–NO –9.5
S–NO –24.0
The peptide orientation in which the N terminus points towards the
tetraloop of the RBE structure is referred to as NL and that in which
the N terminus points towards the 5′,3′ open end of the RBE (a 180°
rotation about an axis perpendicular to the helical axis) is referred to as
NO. The RBE structures ‘A’ and ‘S’ are the structures in which the
nucleotide G71 is in the anti and syn conformation, respectively. The
A–NL_a model has the peptide shifted two base pairs toward the
tetraloop.
looped-out nucleotide A68 has a preference for stacking
interactions with the tryptophan residue Trp12 of
Rev34–50.
Experimental data and the A–NL model 
While some experimental data were used to guide the
model-building process, one of the best tests of our model
was the extent to which it was consistent with experimen-
tal data not used in model building. In this respect, model
A–NL of the complex between Rev34–50 and RBE can
largely rationalize data from protection experiments and
modification interference analyses. For example, residues
Arg2, Arg5, and Arg6 are buried in the major groove of the
RBE, thereby providing a rationale for their observed
resistance to proteolysis [20]. Residue Arg13, on the other
hand, is only partially enveloped by the RNA, which may
explain its greater reactivity towards proteolysis. Model
A–NL does not explain the inaccessibility of Arg17 [20],
although a plausible reason for this discrepancy is that the
experimental studies were performed on the complex of
Rev and RRE whereas our models use minimal binding
domains of the protein and the RNA.
Interference analyses with the RNA also support our
model. The phosphate groups of nucleotides U45, G46,
G47 and U66 cannot be ethylated [10] or converted to
phosphonates [22] without loss of binding activity. In
A–NL, the phosphate groups adjacent to U45, G46 and
G47 are predicted to be involved in specific hydrogen
bonding interactions with peptide sidechains, as indicated
in Table 3. Further, the phosphate groups adjacent to G67
and U66 are involved in electrostatic interactions with
Arg2. Similarly, many of the guanine bases within the
internal loop, in particular those phosphate groups associ-
ated with residues G46, G67, G70 and G71, cannot be
modified without loss of binding activity [10] and are pre-
dicted to be involved in interactions with peptide
sidechains (Table 3).
In contrast, N7 and O6 of G48 can be chemically modified
without loss of binding [15]. This result can be explained
by the A–NL model, in which no direct interactions
between G48 and the peptide are observed. Similarly, for
both the ‘A’ and ‘S’ structures of the RBE, the N7 of G71
is located in the minor groove while that of G48 is in the
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Figure 4
Stereoview of model A-NL. (a) Stereoview of
model A–NL of the Rev34–50–RBE complex.
The internal loop region of RBE (nucleotides
G46, G47 and G48 on the right side and
G70, G71 and A73 on the left side) is
highlighted in yellow. Amino acids Arg2, Arg5,
Arg6 and Arg11 are in green, Asn7 and Thr1
in orange, and Trp12 in violet. (b) Close-up
stereoview of important hydrogen bonds.
Nucleotides G47, G48 and C49 on the right
side and G70, G71 and A73 on the left side
are in yellow. Arg5 (on the top) is in purple as
is Arg6 (on the bottom). Asn7 is in orange.
Hydrogen bonds are indicated by dashed
lines.
major groove. The A–NL model predicts that this non-
Watson–Crick base pair should not be involved in any
direct interactions. This prediction is consistent with
binding studies in which G48 and G71 were substituted
with 7-deazaguanosine [15] and further buttresses the con-
clusion that the non-Watson–Crick pairing aids in estab-
lishing a matrix of negatively charged phosphates that are
contacted by positively charged arginine residues. 
Probing interactions between Rev34–50 and the RBE with
nucleotide substitutions
In order to experimentally verify the model A–NL, inter-
actions between Rev34–50 and several RBE sequence vari-
ants were assessed. Sequence substitutions in the RBE
were chosen to probe the model because individual hydro-
gen bonds between the peptide sidechains and nucleotide
bases could be assessed. In addition, the effects of the
nucleotide substitutions on the structure could be quickly
and easily modelled and the modelling results compared
with experiment.
The model predicts that the O6 position of G67 interacts
with the guanidino group of Arg2. A G67→A nucleotide
substitution replaces O6, a hydrogen bonding acceptor, with
an exocyclic amine, a hydrogen bond donor. As expected,
binding of this RBE variant to Rev34–50 is severely compro-
mised (Table 4). Obviously, this result could be due to dis-
ruption of the C51–G67 base pair and a more global
alteration of the RBE structure rather than the loss of a par-
ticular intermolecular hydrogen bond. Therefore, to mini-
mize possible structural disruptions the double substitution
G67→A; C51→U was also synthesized. This variant also
failed to bind Rev34–50, emphasizing that a critical sequence-
specific interaction had been affected. Similar predictions
were made and confirmed for interactions between Arg5
and RNA with single G70→A and the double G70→A;
C49→U nucleotide substitutions.
In contrast, residue G46 is predicted to interact with
Arg11 of Rev34–50 via its N7 position and with Arg8 via an
adjacent phosphate. Interactions with a G46→A variant
are thus expected to hinge on whether or not this substitu-
tion results in a conformational alteration of the RBE,
rather than the disruption of a particular hydrogen bond.
Modelling of the G46→A nucleotide variant suggests that
the formation of an A–C pair between G46→A and C74
would modify the local backbone conformation of this
base pair, resulting in a loss of hydrogen bonding to N7
and the adjacent phosphate. Reversal to a canonical
Watson–Crick base pair should restore local geometry and
hence binding activity. In agreement with our expecta-
tions, the G46→A single substitution variant cannot bind
Rev34–50, whereas the G46→A; C74→U double substitu-
tion has more than half the binding activity of the wild-
type RBE (Table 4). This pattern of suppression is
consistent with our model, but contrasts with that seen for
G70 and G67, where the lack of the guanosine O6 atom
cannot be corrected by a double nucleotide substitution.
Not all nucleotide substitutions compromise binding activ-
ity. The triple nucleotide substitution G50→A; A68→C;
C69→A, originally identified by in vitro selection [16],
shows improved binding activity both in vitro and in vivo.
In accord with these findings, the Rev peptide also binds to
this triple substitution (Table 4). Also, the series G48→A,
G48→A; G71→A and G48→A; G71→A; U72→C do not
appreciably affect binding. These results again accord with
the fact that none of these residues is predicted to be
involved in base-specific interactions with the peptide.
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Table 3
The hydrogen bonding interactions between the residues of
the RBE and the sidechains of the Rev34–50 peptide predicted
by the A–NL model. 
RBE groups Peptide groups
1 G48:O1P Thr1*
2 G67:O6 Arg2
3 G70:O6,N7; C69:O1P Arg5
4 G70:O1P Arg6
5 A73:N6 Asn7†
6 G47:O6 Asn7‡
7 G46,G47:O1P Arg8
8 A68:O1P; C69:O2P Arg9
9 U45:O1P; G46:O1P,N7 Arg11
10 G71:O1P Arg13
*Hydroxyl group. †Carbonyl group. ‡Amide group.
Table 4
Summary of gel shifts measured with the Rev34–50 peptide and
the RBE mutants. 
RNA % Binding of Rev34–50
RBE 100%
G46→A; C74→U 72%
G48→A 74%
G48→A; G71→A 110%
G48→A; G71→A; U72→C 100%
G67→A 16%
G67→A; C51→U 49%
G50→A; A68→C; C69→A 150%
The numbers represent the average percentages of RNA that had a
modified mobility compared to the wild-type complex in duplicate
experiments. The single mutants G70→A and G46→A and the double
mutant G70→A; C49→U showed no shifts with Rev34–50.
Conclusions
We have used computer docking and energy minimization
procedures to model the molecular recognition between a
peptide from BIV Tat and the Tat-responsive element,
and between the Rev34–50 peptide and the Rev-binding
element. In so doing, we have established an energy crite-
rion to evaluate the orientation and register of
peptide–RNA complexes. While this approach is not able
to distinguish between closely related structures and may
not accurately predict the precise conformation of either
the isolated RNA or the isolated peptide, it does provide
experimentally verified insights into base-specific and
backbone-specific interactions.
As observed in our earlier study [11], a wide major groove
forced open by noncanonical base pairs in the internal
loop of RBE (Figs 1,3) can accommodate the -helix with
amino acids having long sidechains (Fig. 4). In addition,
functional groups presented in the wide major groove, and
correspondingly shielded in the regular A-form RNA
helix, serve as sites for specific hydrogen bonding to the
peptide. Our model is consistent with protection and
interference data for the peptide–RNA complex and
roughly predicts the relative strength of binding interac-
tions between the peptide and variants of the RBE.
The model that we propose for the Rev34–50–RBE
complex was constructed solely with the information
attributed in this paper. In spite of our confidence in this
model, we must recognize the fact that it is based to a
large extent on the forcefield parameters for molecular
simulation procedures and the conditions used for the
inclusion of solvent and salt effects which are well known
to be approximate.
During the final preparations of this manuscript, an NMR-
generated structure for a Rev peptide–RBE complex
appeared [26]. Although the primary sequence of both
RNA and peptide are slightly different from that in this
report, the overall peptide orientation and register pre-
dicted by our model are identical to that in the NMR
structure. Specific interactions between the asparagine
and arginine residues in the NMR structure are duplicated
in our model, i.e. the contacts between Asn7 and the two
nucleotides G47 and A73 and between the residue Arg2
and nucleotide G67. In addition, most phosphate back-
bone contacts that we have predicted are in good agree-
ment with the NMR structure, while the prediction of the
van der Waals’ contacts are, perhaps expectedly, less suc-
cessful. Both represent the peptide conformation as close
to an ideal -helix. Encouraged by the global and local
structural similarity between these two structures, we are
presently assessing the robustness of our model through a
detailed comparison of local interactions between the
RNA and peptide against those determined by this NMR
structure.
Materials and methods
Materials
The listed sequences represent the nontemplate strand of a double-
stranded DNA oligomer; all of these sequences were fused to a T7
RNA polymerase promoter (5′-GGTAATACGACTCACTATA-3′), the
position of which is indicated by an X in the following sequences. The
underlined positions represent substitutions relative to the wild-type
RBE.
RBE 5′-XGGGTGGGCGCACGTTCGCGTGACGGTA-
CACC-3′
G46→A 5′-XGGGTAGGCGCACGTTCGCGTGACGGTA-
CACC-3′
G46→A;C74→T 5′-XGGGTAGGCGCACGTTCGCGTGACGGTAT-
ACC-3′
G50→A;A68→C;C69→A 5′-XGGGTGGGCACACGTTCGCGTGCAGGTA-
CACC-3′
G70→A 5′-XGGGTGGGCGCACGTTCGCGTGACAGTA-
CACC-3′
C49→T;G70→A 5′-XGGGTGGGTGCACGTTCGCGTGACAGTA-
CACC-3′
G48→A 5′-XGGGTGGACGCACGTTCGCGTGACGGTA-
CACC-3′
G48→A;G71→A 5′-XGGGTGGACGCACGTTCGCGTGACGATA-
CACC-3′
G48→A;G71→A;T72→C 5′-XGGGTGGACGCACGTTCGCGTGACGACA-
CACC-3′
G67→A 5′-XGGGTGGGCGCACGTTCGCGTAACGGTA-
CACC-3′
G67→A;C51→T 5′-XGGGTGGGCGTACGTTCGCGTAACGGTA-
CACC-3′
The sequence of the Rev34–50 peptide was NH2-RQARRNRRRRWR-
ERQR-CONH2 (carboxamide). The peptide was prepared as previously
described by Xu and Ellington [27] and its purity was determined by
HPLC and mass spectrometry. The amount of peptide to be used in
gel-shift reactions was determined by HPLC analysis of dissolved
samples.
Docking and simulations
The initial structure of the Rev34–50 peptide was the canonical -helical
form generated by the MSI graphics software INSIGHT II (version
2.3.5, MSI Inc, San Diego, CA). The C terminus of the peptide was
modified to a carboxamide group. Amino acid sidechains were initially
represented in their extended conformations, and arginine and glutamic
acid sidechains were represented in their fully charged forms. The RBE
structure ‘A’ (PDB ID 163D) was generated by energy optimization of
the RBE model previously derived using constraint satisfaction
program MC-SYM [11]. In the ‘A’ structure, nucleotide A68 was
bulged out of the RNA helix and the nucleotide G71 was in the anti
conformation. A similar RBE structure, ‘S’, was obtained by energy
optimization of the RBE model using the constraint satisfaction
approach but specified a syn conformation for the G71 nucleotide. It
should be noted that this conformation was also observed during the
dynamics simulations of ‘A’. As stated in the text, the two initial RBE
structures were used to evaluate the conformational preference of the
G71 nucleotide in the context of the complex.
The electrostatic potential around the RBE was calculated using the
finite difference solution to the nonlinear Poisson–Boltzmann equation
implemented in the Delphi program of the MSI software package. The
dielectric constant of solvent (represented as a continuum model) and
the RNA were included in these calculations. Using the electrostatic
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potential map around the RBE, models for the peptide–RNA complex
were constructed using the MSI software module DOCKING. Electro-
static and van der Waals’ interactions between the peptide and the
RNA were minimized while orienting the peptide in the field of the RNA.
From several possible juxtapositions of the peptide with respect to the
RNA, preferred conformations were selected based first on a low non-
bonded interaction energy and then on an optimum electrostatics
energy for the entire assembly. The models R-C1, R-C2 and I for the
BIV Tat–TAR peptide–RNA complex were derived in the same way
starting with the coordinates of the complex [6] provided to us by
JD Puglisi (University of California at Santa Cruz).
The docked assemblies, A–NL, A–NO, S–NL and S–NO, derived from
the initial RBE structures ‘A’ and ‘S’ and the Rev34–50 peptide were
subsequently optimized using the energy minimization procedure in the
molecular mechanics package Discover (version 2.96, MSI Inc) inter-
faced with the AMBER 2.0 forcefield [28,29]. Energy minimizations
were performed in vacuo using the conjugate gradient minimizer and a
convergence criterion of 0.5 kcal mol–1 Å–2 maximum derivative. A dis-
tance-dependent dielectric constant,   = 4r, was used to simulate the
screening effects of the solvent and a nonbonded cut-off distance of
15 Å was used in all energy calculations. Distance constraints were
imposed on all base-paired hydrogen bonding atoms within the RNA
and on atom pairs within the UUCG tetraloop based on its NMR struc-
ture [29]. The distance constraint was a harmonic potential function
with a force constant of 20 kcal mol–1 Å–2.
In order to improve interactions between the peptide and the RNA, in
vacuo dynamics simulations of the minimized form of the complex model
A–NL were performed using the Discover package and the AMBER
forcefield parameters. The minimized complex was gradually heated to
300 K in steps of 50 K over 500 steps with a timestep of 1 fs. The
dielectric constant, nonbonded cut-offs and distance constraints used
were the same as in the minimization calculations. In addition to the
hydrogen bonding constraints within the RNA, weak harmonic distance
restraints between the peptide and RNA were enforced with a force
constant of 10 kcal mol–1 Å–2. A 20 ps trajectory of the complex at 300
K was run during which coordinates were stored every 0.5 ps. A single
average structure of the last 15 ps of the trajectory was used to identify
interactions between the Rev34–50 peptide and the RBE.
Free energy calculations
The total electrostatic free energy of a molecule is represented as the
sum of the two contributions:
G = Gcoul + GRF (1)
where Gcoul is the coulombic energy of all the charges in the mole-
cule and GRF is the reaction field energy, i.e. the energy arising from
polarizing the environment of the molecule [31]. These two compo-
nents of the electrostatic energy were calculated for the starting con-
formations of RBE, ‘A’ and ‘S’, and for the Rev34–50 peptide by solving
their nonlinear Poisson–Boltzmann equation. Their overall electrostatic
energies are referred to as GRNA and Gpeptide, respectively. The
electrostatic energies of the four Rev34–50–RBE complexes were calcu-
lated in the same manner using the Delphi module [31,32] of the MSI
software. All calculations involved the use of a 653 lattice and a 0.75 Å
spacing between grid points for each of the molecules. The potential at
the boundaries of the grid were calculated using the Debye–Hückel
term with AMBER charges assigned to each atom in the molecule. In
all calculations, the charges were treated as embedded in a low dielec-
tric medium (  = 2) made up of the volume enclosed by the solvent-
accessible surface of the molecule (calculated with a probe radius =
1.4 Å [33]). In each case, the solvent was treated as a continuum
model (  = 80) with a 2.0 Å ion exclusion radius.
During docking, since the peptide approached the RNA from an infinite
separation, the binding free energy of the models for the complex was
calculated according to equation 2 [33,34]:
Gbinding = Gcomplex – {GRNA + Gpeptide} (2)
where G is determined from the Delphi calculations according to
equation 1. Since the binding process involved the association of two
oppositely charged centres, we chose the electrostatic component of
the binding free energy as a useful index for characterizing the proba-
ble juxtaposition of the peptide in the complex.
The electrostatic free energy of the original BIV Tat–TAR complex [6],
different incorrect models and the uncomplexed TAR RNA and Tat
peptide were calculated in a similar manner.
Generation of electrostatic surfaces
The electrostatic potential energy surfaces of Rev34–50 and the RBE
were generated with the INSIGHT module of the MSI software via
potential energy grids that were in turn calculated based on the finite
difference calculations mentioned above. Potential energy surfaces
were mapped using a colour ramp.
Transcription
DNA oligomers and their complements were heated to 95°C for 5 min
in 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA and allowed to
anneal by cooling to room temperature over 30 min. Transcription reac-
tions were carried out using an Ampliscribe kit (Epicentre Technolo-
gies, Madison, WI) according to the manufacturer’s instructions; 1  l
of radiolabel (-[32P]UTP, 3000 Ci mmol–1, 10 mCi ml—1) was incorpo-
rated into each 10  l reaction. Transcripts were purified on a denatur-
ing polyacrylamide gel. The amount of RNA that was to be used in
gel-shift reactions was determined by measuring the absorbance of the
sample at 260 nm.
Gel shift
The ability of RNAs to bind to free peptide was assayed by gel-mobility
shift. Radiolabelled RNA samples were thermally equilibrated in 50 mM
HEPES, pH 7.4; 100 mM NaCl by heating to 75°C for 3 min and then
cooling to ambient temperature over 5 min. RNAs (0.5  g, 1.2  M)
were mixed with peptides (25 ng; 1.0 µM) in 10 µl total volume of 1 ×
Shift Buffer (10 mM HEPES, pH 7.4; 100 mM KCl; 1 mM DTT; 1 mM
MgCl2; 1 mM EDTA; 50  g ml–1 tRNA; 5% glycerol). The binding
reaction was incubated on ice for 30 min. Peptide–RNA complexes
were separated from free RNA by electrophoresis on a 12% polyacry-
lamide gel (29:1 acrylamide : bisacrylamide; 1 × TBE) at 8 W for 3 h.
The temperature of the gel remained at 4–7°C throughout the run.
Radiolabelled bands were visualized and quantitated using a Phospho-
rimager (Molecular Dynamics, Sunnyvale, CA).
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